Actinium Pharmaceuticals, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-33.9M | $-38.2M | $-48.8M | $-33.0M | $-24.8M | $-22.2M | $-21.9M | $-23.7M |
| Depreciation & Amortization | $173.0K | $197.0K | $207.0K | $699.0K | $524.0K | $447.0K | $420.0K | $50.7K |
| Depreciation | $173.0K | $197.0K | $207.0K | $152.0K | $105.0K | $54.0K | $54.0K | $50.7K |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $9.2M | $5.3M | $3.8M | $2.8M | $1.7M | $1.3M | $1.3M | $1.8M |
| Net Cash from Operating Activities | $-24.6M | $-33.1M | $-47.3M | $8.6M | $-20.9M | $-21.6M | $-21.5M | $-20.6M |
| Investing Activities | ||||||||
| Capital Expenditures | $104.0K | $11.0K | $153.0K | $366.0K | $133.0K | $253.0K | $64.0K | $96.1K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-104.0K | $-11.0K | $-153.0K | $-366.0K | $-133.0K | $-253.0K | $-64.0K | $-96.1K |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $-217.0K | $29.3M | $14.9M | $23.1M | $35.2M | $76.2M | $17.1M | $17.0M |
| Net Change in Cash | $-24.9M | $-3.8M | — | $31.4M | $14.2M | $54.3M | $-4.4M | $-3.7M |
| Free Cash Flow | $-24.7M | $-33.1M | $-47.5M | $8.3M | $-21.0M | $-21.9M | $-21.5M | $-20.7M |